trending Market Intelligence /marketintelligence/en/news-insights/trending/RxWq1PAaz1fEP-gaBMYk4A2 content esgSubNav
In This List

Agios submits leukemia drug application to US FDA

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch

Blog

Perspectives from China: Chinese M&A in 2022


Agios submits leukemia drug application to US FDA

Agios Pharmaceuticals Inc. filed an application seeking approval for ivosidenib from the U.S. Food and Drug Administration.

The investigational oral treatment, also known as AG-120, is meant for patients whose acute myeloid leukemia patients whose disease has either returned or is resistant to treatment and exhibits the isocitrate dehydrogenase-1, or IDH1, mutation.

The Cambridge, Mass.-based company is seeking a priority review of the application which is supported by data from the ongoing phase 1 dose-escalation and expansion study of ivosidenib in patients with advanced hematologic malignancies and an IDH1 mutation.